Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 6 and 59 months~* Weight ≥ 5 Kg~* Slide-confirmed infection with Plasmodium falciparum only (no mixed infections)~* Asexual parasite density between 2000 and 200000/µl of blood~* Measured axillary temperature ≥ 37.5°C~* Ability to swallow oral medication~* High probability of respecting the follow-up visits (residence within 1 hour walking distance from the OPD, no upcoming travel plans, etc.)~* Informed consent from a parent or caretaker aged at least 18 years.~Exclusion Criteria:~* • General danger signs according to the WHO definition (Appendix 5.1.1)~  * Signs of severe/complicated malaria according to the WHO definition (Appendix 5.1.2)~ * Severe anaemia (haemoglobin \< 5 g/dL)~ * Known history of hypersensitivity to any of the study drugs~ * Severe acute malnutrition (as defined by a weight-for-height below -3 Z-score and/or symmetrical oedemas involving at least the feet)~ * Concomitant febrile illness due to causes other than malaria with the potential to confound study outcome (measles, acute lower tract respiratory infection, otitis media, tonsillitis, abscesses, severe diarrhoea with dehydration).~ * Having received already a full course of the treatment (or one of the treatments) under study in the previous 28 days (as indicated by the parent/caretaker). Note that previous incomplete anti-malarial intake of treatments under study, or previous intake of anti-malarials not under study, are not exclusion criteria, but details of any such intake should be recorded carefully.~ * History of hypersensitivity reactions or contra-indications to any medicines being tested.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Amodiaquine-Artesunate (ASAQ) (Type: ACTIVE_COMPARATOR): Treatment regimen consisted of Amodiaquine-Artesunate (ASAQ) fixed dose (FD) (Winthrop Sanofi Aventis), given as 1 tablet/day 3 days (5-8 kg 1 tab of 25mg artesunate/67.5 mg amodiaquine base, 9-17 kg 50 mg artesunate/135 mg amodiaquine base)
- Artemether-Lumefantrine (AL) (Type: ACTIVE_COMPARATOR): Treatment consisted of Artemether-Lumefantrine (AL) (Coartem, Novartis) given as six twice/daily doses over three days (5-14 kg 1tab of 20mg artemether/120mg lumefantrine BD, 15-24 kg 2tabs of 20mg artemether/120mg lumefantrine BD with fatty food).

Based on this trial design, predict the completion outcome and termination type (if applicable).